References
- Rowe JM. Perspectives on current survival and new developments in AML. Best Pract Res Clin Haematol. 2021;34(1):101248. doi:10.1016/j.beha.2021.101248
- Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53–61. doi:10.1182/blood-2015-08-604520
- Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314(8):811–822. doi:10.1001/jama.2015.9643
- Ravandi F, Cortes J, Faderl S, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood. 2010;116(26):5818–5823; quiz 6153. doi:10.1182/blood-2010-07-296392
- Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. doi:10.1182/blood.2022016867
- Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program. 2009;2009(1):385–395. doi:10.1182/asheducation-2009.1.385
- Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1
- Liersch R, Müller-Tidow C, Berdel WE, et al. Prognostic factors for acute myeloid leukaemia in adults – biological significance and clinical use. Br J Haematol. 2014;165(1):17–38. doi:10.1111/bjh.12750
- Samra B, Richard-Carpentier G, Kadia TM, et al. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J. 2020;10(5):47. doi:10.1038/s41408-020-0316-3
- Han HS, Rybicki LA, Thiel K, et al. White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia. Leuk Lymphoma. 2007;48(8):1561–1568. doi:10.1080/10428190701474373
- Marras T, Dettori M, Caocci G, et al. White blood cell count nadir and duration of aplasia do not associate with treatment outcome in adult patients with acute myeloid leukemia undergoing intensive chemotherapy. Chemotherapy. 2020;65(3-4):110–114. doi:10.1159/000509816
- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
- Wang Y, Probin V, Zhou D. Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy. Curr Cancer Ther Rev. 2006;2(3):271–279. doi:10.2174/157339406777934717
- Zhang Y, Dai K, Zhang Q, et al. Normal absolute monocyte count in combination with normal/high absolute lymphocyte count at the time of relapse is associated with improved survival in patients with early relapsed acute myeloid leukemia. Cancer Invest. 2021;39(6–7):550–558. doi:10.1080/07357907.2021.1933013